Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + apatinib
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-A1811 + apatinib is a combination therapy under clinical investigation for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. SHR-A1811 is an antibody-drug conjugate (ADC) targeting HER2, developed by Hengrui Medicine, while apatinib is an orally administered small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking angiogenesis and tumor proliferation. Apatinib has been approved in China for advanced gastric cancer after failure of prior therapies and has shown activity in other solid tumors. The combination aims to leverage the targeted cytotoxicity of the ADC with antiangiogenic effects to improve outcomes in advanced cancers[1][2][3][6][7][8].
- Brand names
- Aitanrivoceranib
- Other names
- SHR-A1811SHR-A-1811SHR-A 1811apatinibrivoceranib
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on SHR-A1811 + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + apatinib.